Insider · CIK 0001241752

EBERT CHARLES D

Reports to the SEC for 2 companies · CORONA, CA

sec.gov

Transactions

Companies

Filings

CIK

0001241752

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2013-11-06	Allergan plcS Sale	SVP, BRANDS R&D	SSale	−10.9K sh	$158.75	−$1.73M	7,611
2013-10-01	Allergan Finance LLCD Disposition to Issuer	Sr. VP, Research & Development	DDisposition to Issuer	−18.5K sh	—	—	0
2013-10-01	Allergan plcA Award	SVP, BRANDS R&D	AAward	+18.5K sh	—	—	18,488
2013-09-30	Allergan Finance LLCA Award	Sr. VP, Research & Development	AAward	+12.2K sh	—	—	32,182
2013-09-30	Allergan Finance LLCF Tax Payment	Sr. VP, Research & Development	FTax Payment	−13.7K sh	$144.00	−$1.97M	18,488
2013-08-05	Allergan Finance LLCS Sale	Sr. VP, Research & Development	SSale	−8,244 sh	$136.25	−$1.12M	19,970
2013-08-05	Allergan Finance LLCF Tax Payment	Sr. VP, Research & Development	FTax Payment	−8,244 sh	$136.25	−$1.12M	19,970
2013-03-06	Allergan Finance LLCA Award	Sr. VP, Research & Development	AAward	+2,653 sh	—	—	26,487
2013-03-06	Allergan Finance LLCA Award	Sr. VP, Research & Development	AAward	+1,727 sh	—	—	28,214
2013-03-05	Allergan Finance LLCF Tax Payment	Sr. VP, Research & Development	FTax Payment	−1,331 sh	$86.46	−$115K	23,834
2013-03-02	Allergan Finance LLCF Tax Payment	Sr. VP, Research & Development	FTax Payment	−1,761 sh	$85.54	−$151K	25,165
2012-03-14	Allergan Finance LLCF Tax Payment	Sr. VP, Research & Development	FTax Payment	−1,265 sh	$59.21	−$74.9K	26,926
2012-03-08	Allergan Finance LLCA Award	Sr. VP, Research & Development	AAward	+3,342 sh	—	—	25,625
2012-03-08	Allergan Finance LLCA Award	Sr. VP, Research & Development	AAward	+2,566 sh	—	—	28,191
2012-02-29	Allergan Finance LLCM Exercise/Conversion	Sr. VP, Research & Development	MExercise/Conversion	+1,000 sh	$25.64	+$25.6K	27,264
2012-02-29	Allergan Finance LLCS Sale	Sr. VP, Research & Development	SSale	−1,000 sh	$58.77	−$58.8K	26,264
2012-02-29	Allergan Finance LLCS Sale	Sr. VP, Research & Development	SSale	−3,981 sh	$58.81	−$234K	22,283
2012-02-29	Allergan Finance LLCIncentive Stock Options to Purchase Common StockM Exercise/Conversion	Sr. VP, Research & Development	MExercise/Conversion	−1,000 sh	—	—	0
2012-02-24	Allergan Finance LLCF Tax Payment	Sr. VP, Research & Development	FTax Payment	−1,458 sh	$58.17	−$84.8K	26,264
2011-06-01	Allergan Finance LLCS Sale	Sr. VP, Research & Development	SSale	−2,635 sh	$64.45	−$170K	27,722
2011-03-11	Allergan Finance LLCF Tax Payment	Sr. VP, Research & Development	FTax Payment	−616 sh	$56.89	−$35K	30,357
2011-03-05	Allergan Finance LLCF Tax Payment	Sr. VP, Research & Development	FTax Payment	−1,295 sh	$56.79	−$73.5K	30,973
2011-03-03	Allergan Finance LLCM Exercise/Conversion	Sr. VP, Research & Development	MExercise/Conversion	+7,500 sh	$48.85	+$366K	39,768
2011-03-03	Allergan Finance LLCS Sale	Sr. VP, Research & Development	SSale	−7,500 sh	$56.36	−$423K	32,268
2011-03-03	Allergan Finance LLCNon-qualified Options to Purchase Common StockM Exercise/Conversion	Sr. VP, Research & Development	MExercise/Conversion	−7,500 sh	—	—	0
2011-03-02	Allergan Finance LLCA Award	Sr. VP, Research & Development	AAward	+7,119 sh	—	—	32,268
2010-12-06	Allergan Finance LLCS Sale	Sr. VP, Research & Development	SSale	−3,639 sh	$51.00	−$186K	25,149
2010-09-01	Allergan Finance LLCF Tax Payment	Sr. VP, Research & Development	FTax Payment	−216 sh	$44.15	−$9,536.4	28,788
2010-03-14	Allergan Finance LLCF Tax Payment	Sr. VP, Research & Development	FTax Payment	−1,265 sh	$41.37	−$52.3K	29,004
2010-03-12	Allergan Finance LLCM Exercise/Conversion	Sr. VP, Research & Development	MExercise/Conversion	+1,600 sh	$38.92	+$62.3K	31,869
2010-03-12	Allergan Finance LLCM Exercise/Conversion	Sr. VP, Research & Development	MExercise/Conversion	+6,400 sh	$38.92	+$249K	38,269
2010-03-12	Allergan Finance LLCM Exercise/Conversion	Sr. VP, Research & Development	MExercise/Conversion	+4,843 sh	$26.14	+$127K	43,112
2010-03-12	Allergan Finance LLCM Exercise/Conversion	Sr. VP, Research & Development	MExercise/Conversion	+8,757 sh	$26.14	+$229K	51,869
2010-03-12	Allergan Finance LLCM Exercise/Conversion	Sr. VP, Research & Development	MExercise/Conversion	+316 sh	$35.11	+$11.1K	52,185
2010-03-12	Allergan Finance LLCM Exercise/Conversion	Sr. VP, Research & Development	MExercise/Conversion	+3,684 sh	$35.11	+$129K	55,869
2010-03-12	Allergan Finance LLCM Exercise/Conversion	Sr. VP, Research & Development	MExercise/Conversion	+1,001 sh	$25.64	+$25.7K	56,870
2010-03-12	Allergan Finance LLCM Exercise/Conversion	Sr. VP, Research & Development	MExercise/Conversion	+1,999 sh	$25.64	+$51.3K	58,869
2010-03-12	Allergan Finance LLCS Sale	Sr. VP, Research & Development	SSale	−1,200 sh	$40.88	−$49.1K	57,669
2010-03-12	Allergan Finance LLCS Sale	Sr. VP, Research & Development	SSale	−1,500 sh	$40.86	−$61.3K	56,169
2010-03-12	Allergan Finance LLCS Sale	Sr. VP, Research & Development	SSale	−850 sh	$40.87	−$34.7K	55,319
2010-03-12	Allergan Finance LLCS Sale	Sr. VP, Research & Development	SSale	−200 sh	$40.88	−$8,175	55,119
2010-03-12	Allergan Finance LLCS Sale	Sr. VP, Research & Development	SSale	−200 sh	$40.87	−$8,173	54,919
2010-03-12	Allergan Finance LLCS Sale	Sr. VP, Research & Development	SSale	−24.7K sh	$40.85	−$1.01M	30,269
2010-03-12	Allergan Finance LLCNon-Qualified Options to Purchase Common StockM Exercise/Conversion	Sr. VP, Research & Development	MExercise/Conversion	−1,600 sh	—	—	0
2010-03-12	Allergan Finance LLCNon-Qualified Options to Purchase Common StockM Exercise/Conversion	Sr. VP, Research & Development	MExercise/Conversion	−6,400 sh	—	—	0
2010-03-12	Allergan Finance LLCIncentive Stock Options to Purchase Common StockM Exercise/Conversion	Sr. VP, Research & Development	MExercise/Conversion	−4,843 sh	—	—	0
2010-03-12	Allergan Finance LLCNon-Qualified Options to Purchase Common StockM Exercise/Conversion	Sr. VP, Research & Development	MExercise/Conversion	−8,757 sh	—	—	3,400
2010-03-12	Allergan Finance LLCIncentive Stock Options to Purchase Common StockM Exercise/Conversion	Sr. VP, Research & Development	MExercise/Conversion	−316 sh	—	—	0
2010-03-12	Allergan Finance LLCNon-Qualified Options to Purchase Common StockM Exercise/Conversion	Sr. VP, Research & Development	MExercise/Conversion	−3,684 sh	—	—	0
2010-03-12	Allergan Finance LLCIncentive Stock Options to Purchase Common StockM Exercise/Conversion	Sr. VP, Research & Development	MExercise/Conversion	−1,001 sh	—	—	1,000

Recent filings

Accepted (ET)
Nov 84
Actavis plc0001179110-13-016337
SEC(opens sec.gov)
Oct 34
Actavis plc0001179110-13-015197
SEC(opens sec.gov)
Oct 24
Actavis, Inc.0001179110-13-015052
SEC(opens sec.gov)
Aug 134/A
Actavis, Inc.0001179110-13-013101
SEC(opens sec.gov)
Aug 64
Actavis, Inc.0001179110-13-012762
SEC(opens sec.gov)
Mar 84
EBERT CHARLES D0001179110-13-004742
SEC(opens sec.gov)
Mar 74
EBERT CHARLES D0001179110-13-004505
SEC(opens sec.gov)
Mar 54
EBERT CHARLES D0001179110-13-004330
SEC(opens sec.gov)
Mar 164
EBERT CHARLES D0001179110-12-005195
SEC(opens sec.gov)
Mar 124
EBERT CHARLES D0001179110-12-004793
SEC(opens sec.gov)
Mar 14
EBERT CHARLES D0001179110-12-003877
SEC(opens sec.gov)
Feb 284
EBERT CHARLES D0001179110-12-003649
SEC(opens sec.gov)
Jun 14
EBERT CHARLES D0001179110-11-009096
SEC(opens sec.gov)

Companies

Address

C/O WATSON PHARMACEUTICALS, INC. 311 BONNIE CIRCLE

CORONA, CA, 92880